Ami Lifesciences received CEP approval for Rivaroxaban
Ami Lifesciences was founded with the goal of changing the way in which quality medicines are delivered to people in need with significant global player by providing high quality and affordable API’s
We are delighted to inform you that we have received CEP approval for Rivaroxaban, which is used as an anti-coagulating agent, for the treatment of Deep Vein Thrombosis and Pulmonary Embolism.
Our heartfelt thanks to everyone who has contributed to this achievement, from our dedicated team to our partners and stakeholders.
